For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Transfers Marketing of Kremezin in Japan to MTPC
January 24, 2011
- BI, Eli Lilly Tie Up to Develop Antidiabetic Agents
January 24, 2011
- GSK Licenses Parkinson's Disease Drug from Impax
January 24, 2011
- AZ Enters 2nd Decade of Leap in 2011: President Kato
January 24, 2011
- Teijin Pharma to Market Kenketsu Venilon, Anact C in Kyushu
January 24, 2011
- Astellas to Review Strategic Alternatives for Prosidion
January 24, 2011
- Eisai Signs PPP to Increase Patients' Access to Medicines in India
January 24, 2011
- Kyowa Kirin to Reinforce GMP Compliance
January 24, 2011
- AnGes MG to Codevelop Antibacterial Spray with Hospital Group
January 24, 2011
- JMIRI Launches Web Service for Prescription Record Analysis
January 24, 2011
- Teijin Pharma to Launch TMX-67 in Emerging Countries in 2013-2014
January 24, 2011
- Market for Drugs for Alzheimer's Disease to Reach ¥290 Bil. in 2020: Seed Planning Survey
January 24, 2011
- FJPWA to Do Utmost for Full Introduction of Premium for New Drug Development: Chairman Bessho
January 24, 2011
- 76 Actos Generics Approved from 27 Companies
January 24, 2011
- Qol Considers Introducing Point Cards for Drug Dispensing Services
January 24, 2011
- Pfizer to Market Generics of Over 20 APIs in 2011
January 24, 2011
- classA Network Considers Introducing Point Service Program
January 24, 2011
- Small Generic Makers to Increasingly Specialize in Development, Manufacturing: JGA President Sawai
January 24, 2011
- Blopress Remains No. 1 for 7th Term in a Row: Domestic Drug Sales Ranking
January 17, 2011
- Mizuho Securities Lists Halaven, KW-0761 as Promising Anticancer Agents
January 17, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…